Ariad Pharmaceuticals (ARIA) Posts Q2 Loss of 36c; Revs Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street rises on revived AI momentum as earnings season picks up
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts ARIA Hot Sheet
Price: $24.07 --0%
Financial Fact:
Income (loss) from operations: -24.99M
Today's EPS Names:
OMID, SICP, SCKT, More
Financial Fact:
Income (loss) from operations: -24.99M
Today's EPS Names:
OMID, SICP, SCKT, More
Join SI Premium – FREE
Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) reported Q2 loss of ($0.36), $0.18 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $66 thousand versus the consensus estimate of $930 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CTS Corp. (CTS) Tops Q3 EPS by 10c ; Offers Guidance
- Applied Industrial Technologies (AIT) Tops Q1 EPS by 9c ; Offers Guidance
- Sherwin-Williams (SHW) Misses Q3 EPS by 6c; offers guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
